Retrospective analysis of percutaneous transluminal coronary angioplasty and coronary stenting.

To examine long-term efficacy of percutaneous transluminal coronary angioplasty (PTCA), coronary stenting and to assess the factors affecting its efficacy.
A total of 790 patients who underwent successful PTCA and PTCA + stent in this hospital were followed by direct interview or letter. The rate of follow-up was 84.2% and the period of follow-up was 0.9 - 12.7 (3.5 +/- 2.4) years.
During follow-up, 4 (0.5%) patients died, 22 (2.8%) had nonfatal acute myocardial infarction, 10 (1.3%) had coronary artery bypass surgery, and 98 (12.4%) had repeat PTCA. The rate of recurrent angina pectoris was 31.1%. The cardiac event-free survival rate calculated by the Kaplan-Meier method was 88.2% at 1 year and 80.6% at 12.7 years. Cox regression analysis showed that there was a positive correlation between AMI history, stent implantation and the risk of cardiac events, and there was a negative correlation between the number of diseased arteries and the risk of cardiac events. Compared to the PTCA group, patients with PTCA + stent had significantly lower rates of total cardiac events.
The long-term efficacy of PTCA, especially PTCA + stent in Chinese patients was very satisfactory, suggesting that PTCA + stent therapy should be the major treatment for revascularization in patients with coronary heart disease.
AuthorsJilin Chen, Runlin Gao, Qiangjun Cai, Yuejin Yang, Shubin Qiao, Xuewen Qin, Jun Zhang, Min Yao
JournalChinese medical journal (Chin Med J (Engl)) Vol. 115 Issue 4 Pg. 483-6 (Apr 2002) ISSN: 0366-6999 [Print] China
PMID12133279 (Publication Type: Journal Article)
  • Adult
  • Aged
  • Angina Pectoris (etiology)
  • Angioplasty, Balloon, Coronary (adverse effects)
  • Coronary Stenosis (mortality, therapy)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardial Infarction (etiology)
  • Retrospective Studies
  • Stents (adverse effects)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: